«Pharmvestnik» has published an article on the development of B3-MED in the digital medicine sector

In the October issue of the largest information and analytics publication on the pharmaceutical industry, «Pharmaceutical Bulletin», an article titled «Earning on Evidence» was published about the «B3-MED» projects: MedIQ and PharmFrame.

Key facts from the publication:

• Despite the development of the B2B segment, most requests and traffic come from patients. In August 2025 alone, according to Wordstat, there were over 13,000 searches for «medications with proven efficiency» and about 500 for «check a medication for efficiency».
• Publications listing drugs without proven efficacy provoke reactions from manufacturers. Some send pre-trial claims, to which the «B3-MED» team provides well-reasoned responses.
• In 2023, the team launched a module for analyzing more than 300,000 pairs of mediction interactions. The PharmFrame DX service — designed to verify the validity of diagnostic prescriptions — is also being developed.
• The digital products of «B3-MED» are not classified as medical devices, operate without processing personal data, and are registered as information-analytical systems. This is confirmed by a conclusion from VNIIMT of Roszdravnadzor.
• «B3-MED» plans to use real-world clinical practice data to evaluate therapy effectiveness and to ensure integration of PharmFrame and other digital products with medical information systems.

The publication in «Pharmaceutical Bulletin» highlights the recognition of «B3-MED» within the professional community and the company’s significance in the context of the digital transformation of Russian healthcare.